J&J profit boosted by better-than-expected pharma unit sales
Share:
(Reuters) - Johnson & Johnson beat quarterly profit estimates on higher sales at its pharmaceuticals unit even as it faces fierce competition for some of its biggest drugs, sending the company's shares up more than 2 percent.Sales from the business, which accounts for more than half of the company's total revenue, rose 4.1 percent and beat estimates, mainly boosted by demand for Stelara - its treatment for psoriasis and Crohn's disease - as well as cancer drugs Darzalex and Imbruvica."J&J's..